Related references
Note: Only part of the references are listed.Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Klebsiella pneumoniae
Dominika Ojdana et al.
MICROBIAL DRUG RESISTANCE (2019)
Management of KPC-producing Klebsiella pneumoniae infections
M. Bassetti et al.
CLINICAL MICROBIOLOGY AND INFECTION (2018)
In vitro antibacterial activity of fosfomycin combined with other antimicrobials against KPC-producing Klebsiella pneumoniae
Wei Yu et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
Belen Gutierrez-Gutierrez et al.
LANCET INFECTIOUS DISEASES (2017)
Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature
B. Grabein et al.
CLINICAL MICROBIOLOGY AND INFECTION (2017)
Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance
F. Docobo-Perez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Population Pharmacokinetics of Fosfomycin in Critically Ill Patients
Suzanne L. Parker et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Carbapenemase-Producing Klebsiella pneumoniae, a Key Pathogen Set for Global Nosocomial Dominance
Johann D. D. Pitout et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments
Mahableshwar S. Albur et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Evaluation of Double- and Triple-Antibiotic Combinations for VIM- and NDM-Producing Klebsiella pneumoniae by In Vitro Time-Kill Experiments
T. Tangden et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems
George L. Daikos et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Treating infections caused by carbapenemase-producing Enterobacteriaceae
L. S. Tzouvelekis et al.
CLINICAL MICROBIOLOGY AND INFECTION (2014)
In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains
Ebru Evren et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2013)
What is the relevance of fosfomycin pharmacokinetics in the treatment of serious infections in critically ill patients? A systematic review
Suzanne Parker et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2013)
Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens
Zubair A. Qureshi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Predictors of Mortality in Bloodstream Infections Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Importance of Combination Therapy
Mario Tumbarello et al.
CLINICAL INFECTIOUS DISEASES (2012)
Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections
D. Ben-David et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates
G. Samonis et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2012)
Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens
Drosos E. Karageorgopoulos et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
In Vitro Interactions of Antimicrobial Combinations with Fosfomycin against KPC-2-Producing Klebsiella pneumoniae and Protection of Resistance Development
Maria Souli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment
O. Zarkotou et al.
CLINICAL MICROBIOLOGY AND INFECTION (2011)
Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?
G. L. Daikos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2011)
Updated multiplex polymerase chain reaction for detection of 16S rRNA methylases: high prevalence among NDM-1 producers
Beatrice Bercot et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2011)
In vitro evaluation of antibiotic synergy for NDM-1-producing Enterobacteriaceae
Beatrice Bercot et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media
John D. Perry et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Global Spread of Carbapenemase-producing Enterobacteriaceae
Patrice Nordmann et al.
EMERGING INFECTIOUS DISEASES (2011)
Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria
Antonia C. Kastoris et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin
Matthew E. Falagas et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection
Elizabeth B. Hirsch et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Fosfomycin for the treatment of infections caused by Gram-positive cocci with advanced antimicrobial drug resistance: a review of microbiological, animal and clinical studies
Matthew E. Falagas et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections
Nikos Roussos et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Development and Evaluation of a Real-Time PCR Assay for Detection of Klebsiella pneumoniae Carbapenemase Genes
Justin M. Cole et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Fosfomycin: Use beyond urinary tract and gastrointestinal infections
Matthew E. Falagas et al.
CLINICAL INFECTIOUS DISEASES (2008)
Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin
M. E. Falagas et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2008)
Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies
Gopi Patel et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2008)
Mutators among CTX-M β-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance
Matthew J. Ellington et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release
S Eschenburg et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Share Paper
